OXLUMO Continues Upward Market Momentum, Reinforcing RNAi Leadership in Primary ...
The market outlook for OXLUMO reflects a positive trajectory in both market performance and therapeutic potential for treating primary hyperoxaluria type 1. The drug generated approximately USD 167 ...
Pharmabiz2 小时
YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing ...
YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...